Prognostic impact of desmoplastic reaction in esophageal squamous cell carcinoma patients with neoadjuvant therapy

Aim This study aimed to examine the prognostic value of desmoplastic reaction (DR) in esophageal squamous cell carcinoma (ESCC), particularly in patients who received neoadjuvant therapy, such as chemotherapy (NAC) or chemoradiotherapy (NACRT). Method In total, 153 patients with pStage II/III ESCC w...

Full description

Saved in:
Bibliographic Details
Published in:Esophagus : official journal of the Japan Esophageal Society 2023-07, Vol.20 (3), p.474-483
Main Authors: Kouzu, Keita, Kajiwara, Yoshiki, Tsujimoto, Hironori, Mochizuki, Satsuki, Okamoto, Koichi, Shinto, Eiji, Kishi, Yoji, Matsukuma, Susumu, Ueno, Hideki
Format: Article
Language:English
Subjects:
Cancer therapies
Chemoradiotherapy
Clinical outcomes
Esophageal cancer
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Esophageal Squamous Cell Carcinoma
Gastroenterology
Humans
Medical prognosis
Medicine
Medicine & Public Health
Multivariate analysis
Neoadjuvant Therapy
Original Article
Prognosis
Squamous cell carcinoma
Surgical Oncology
Thoracic Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim This study aimed to examine the prognostic value of desmoplastic reaction (DR) in esophageal squamous cell carcinoma (ESCC), particularly in patients who received neoadjuvant therapy, such as chemotherapy (NAC) or chemoradiotherapy (NACRT). Method In total, 153 patients with pStage II/III ESCC were included in this study. Ninety-one patients received neoadjuvant therapy (NAC, 70; NACRT, 21). Patients were classified according to three DR categories based on the presence of keloid-like collagen and/or myxoid stroma. Results In total, 50, 50, and 53 patients were classified as having mature, intermediate, and immature DR, respectively. The weighted kappa coefficient was 0.623 in the patients with preoperative treatments and 0.782, in those without. The 5-year disease-specific survival (DSS) rates in patients with intermediate/immature DR was significantly worse than those with mature DR (40.7% vs. 73.3%, p 
ISSN:1612-9059
1612-9067
DOI:10.1007/s10388-023-00996-z